Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's ...

Novo Nordisk (NVO) has launched its weight-loss drug Wegovy in Thailand, Reuters reported on Monday, citing an executive of ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

But recent weak U.S. prescription data is leading some investors and analysts to question whether that stellar run, which ...

Novo Nordisk has launched its popular weight-loss drug Wegovy in Thailand, marking its first entry into the Southeast Asian ...

A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

On Thursday, Reuters reported weak U.S. prescription data is contributing to investor concerns that Novo Nordisk is no longer ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

LONDON, April 24 (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk (NOVOb.CO), opens new tab has raised its annual sales guidance several times a year.